跳转至内容
Merck

1365065

USP

左旋甲状腺素钠

United States Pharmacopeia (USP) Reference Standard

别名:

左旋甲状腺素钠 水合物, 3,3′,5,5′-四碘代-L-甲状腺原氨酸 单钠盐 水合物, O-(4-羟基-3,5-二碘代苯基)-3,5-二碘代-L-酪氨酸钠 水合物

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H10I4NNaO4 · xH2O
CAS号:
分子量:
798.85 (anhydrous basis)
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

levothyroxine

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

−20°C

SMILES 字串

O.[Na+].N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C([O-])=O

InChI

1S/C15H11I4NO4.Na.H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;1H2/q;+1;/p-1/t12-;;/m0../s1

InChI 密鑰

ANMYAHDLKVNJJO-LTCKWSDVSA-M

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Levothyroxine sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

STOT RE 1

標靶器官

Thyroid,Cardio-vascular system,Kidney

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Mazen Lee Hamad et al.
Pharmaceutical development and technology, 20(3), 314-319 (2013-12-04)
Levothyroxine sodium is an important medication used primarily for treating patients with hypothyroidism. Levothyroxine sodium tablets have been recalled many times since their 1955 introduction to the US market. These recalls resulted from the failure of lots to meet their

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门